|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Manufacturing
revenue and royalties
Manufacturing revenue and royalties from our EDT business
comprise revenue earned from products we manufacture for third
parties and royalties we earn principally on sales by third
parties of products that incorporate our technologies.
Manufacturing revenue and royalties increased 16% to
$269.5 million in 2007 from our 2006 sales level and
increased 14% to $232.4 million in 2006 from
$204.5 million in 2005. The increase in 2007 primarily
reflects continued growth across a number of products in our EDT
portfolio and increased manufacturing activity. The increase in
2006 from our 2005 sales level was principally due to increased
royalties on sales by third parties, primarily TriCor and
Skelaxin. In January 2006, our royalty on Skelaxin changed from
5% on all net sales of the product by King Pharmaceuticals, Inc.
(King) in 2005, to 10% on net sales in excess of
$50.0 million in each calendar year going forward.
Except as noted above, no other single product accounted for
more than 10% of our manufacturing revenue and royalties in
2007, 2006 or 2005. In 2007, 47% of these revenues consisted of
royalties received on products that we do not manufacture,
compared to 44% in 2006 and 34% in 2005.
Potential generic competitors have challenged the existing
patent protection for several of the products from which we earn
manufacturing revenue and royalties. We and our clients defend
our intellectual property rights vigorously. However, if these
challenges are successful, our manufacturing revenue and
royalties will be materially and adversely affected.
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Manufacturing
Revenue and Royalties
Manufacturing revenue and royalties are as follows:
Elan Corporation, plc 2006 Annual
Report 39
Table of Contents
Manufacturing revenue and royalties from our EDT business
comprises revenue earned from products we manufacture for third
parties and royalties we earn principally on sales by third
parties of products that incorporate our technologies.
Manufacturing revenue and royalties increased 12% to
$232.6 million in 2006 from $207.1 million in 2005.
The increase was primarily due to increased royalties on sales
by third parties, primarily Tricor and
Skelaxin®,
and increased manufacturing activity. In January 2006, our
royalty on Skelaxin changed from 5% on all net sales of the
product by King Pharmaceuticals, Inc. (King) in 2005, to 10% on
net sales in excess of $50.0 million per year. Except as
noted above, no other single product accounted for more than 10%
of our manufacturing revenue and royalties in either 2006 or
2005. In 2006, 40% of these revenues consisted of royalties
received on products that we do not manufacture, compared to 34%
in 2005.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. (B) Manufacturing
revenue and royalties
Manufacturing revenue and royalties are as follows (in millions):
Manufacturing revenue and royalties from our EDT business
comprises revenue earned from products we manufacture for third
parties and royalties we earn principally on sales by third
parties of products that incorporate our technologies. The
increase of 58% was primarily due to increased sales by third
parties of products that incorporate Elan’s technologies,
predominantly Tricor, and increased manufacturing activity for
third parties. Except as noted above, no other single product
accounted for more than 10% of our manufacturing revenue and
royalties in either 2005 or 2004. In 2005, 34% of these revenues
consisted of royalties received on products that we do not
manufacture, compared to 19% in 2004.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Manufacturing Revenue and
Royalties
Manufacturing revenue and royalties are as follows:
Manufacturing revenue and royalties from our EDT business
comprises revenue earned from products we manufacture for third
parties, and royalties we earn principally on sales by third
parties of products that incorporate our technologies. The 64%
increase was primarily due to increased sales by third parties
of products that incorporate Elan’s technologies,
principally Tricor, and increased manufacturing activity for
third parties. Except as noted above, no other single product
accounted for more than 10% of our manufacturing revenue and
royalties in either 2005 or 2004. In 2005, 34% of these revenues
consisted of royalties received on products that we do not
manufacture, compared to 16% in 2004.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. (B) Manufacturing
revenue and royalties
Manufacturing revenue and royalties are as follows (in millions):
Manufacturing revenue and royalties comprises of revenue earned
from products we manufacture for third parties, and royalties we
earned on sales by third parties of products that incorporate
our technologies. The increase of 9% in 2004 was primarily
related to additional manufacturing activities. Aside from
Verelan and Diltiazem, no other single product accounted for
more than 10% of our manufacturing revenue and royalties in
either 2004 or 2003. In 2004, 19% of these revenues consisted of
royalties received on products that we do not manufacture,
compared to 12% in 2003.
This excerpt taken from the ELN 6-K filed Oct 27, 2005. Manufacturing revenue and royalties
Manufacturing revenue and royalties from Elan’s Drug Technology business comprises revenue earned from products manufactured for third parties and royalties earned principally on sales by third parties of products that incorporate Elan’s technologies.
Manufacturing revenue and royalties was $57.8 million in the third quarter of 2005, an increase of 99% over the $29.0 million recorded in the third quarter of 2004. This primarily reflects increased sales by third parties of products that incorporate Elan’s technologies, principally TricorTM, and increased manufacturing activity for third parties.
Manufacturing revenue and royalties can be further analyzed as follows:
No product accounted for more than 10% of total manufacturing revenue and royalties in the third quarter of 2005 or 2004, except as noted above. Of the total of $57.8 million in manufacturing revenue and royalties in the third quarter of 2005, 35% (2004: 15%) consisted of royalties received on products that are not manufactured by Elan.
| EXCERPTS ON THIS PAGE:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
